References
- McKhann GM, Knopman DS, Chertkow H et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging – Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dement. 7(3), 263–269 (2011).
- Lan J, Liu J, Zhao Z et al. The peripheral blood of Abeta binding RBC as a biomarker for diagnosis of Alzheimer’s disease. Age Ageing 44(3), 458–464 (2015).
- Veitinger M, Oehler R, Umlauf E et al. A platelet protein biochip rapidly detects an Alzheimer’s disease-specific phenotype. Acta Neuropathol. 128(5), 665–677 (2014).
- Bermejo-Pareja F, Antequera D, Vargas T, Molina JA, Carro E. Saliva levels of Aβ1–42 as potential biomarker of Alzheimer’s disease: a pilot study. BMC Neurol. 10, 108 (2010).
- Shi M, Sui YT, Peskind ER et al. Salivary tau species are potential biomarkers of Alzheimer’s disease. J. Alzheimer’s Dis. 27(2), 299–305 (2011).
- Mattsson N, Zetterberg H, Janelidze S et al. Plasma tau in Alzheimer disease. Neurology 87(17), 1827–1835 (2016).
- Lovheim H, Elgh F, Johansson A et al. Plasma concentrations of free amyloid beta cannot predict the development of Alzheimer’s disease. Alzheimers Dement. doi:10.1016/j.jalz.2016.12.004 (2017) ( Epub ahead of print).
- Kim SM, Song J, Kim S et al. Identification of peripheral inflammatory markers between normal control and Alzheimer’s disease. BMC Neurol. 11, 51 (2011).
- Doecke JD, Laws SM, Faux NG et al. Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch. Neurol. 69(10), 1318–1325 (2012).
- Faria MC, Goncalves GS, Rocha NP et al. Increased plasma levels of BDNF and inflammatory markers in Alzheimer’s disease. J. Psychiatr. Res. 53, 166–172 (2014).
- Cunnane SC, Schneider JA, Tangney C et al. Plasma and brain fatty acid profiles in mild cognitive impairment and Alzheimer’s disease. J. Alzheimers Dis. 29(3), 691–697 (2012).
- Muenchhoff J, Poljak A, Song F et al. Plasma protein profiling of mild cognitive impairment and Alzheimer’s disease across two independent cohorts. J. Alzheimers Dis. 43(4), 1355–1373 (2015).
- Pan X, Fei G, Lu J et al. Measurement of blood thiamine metabolites for Alzheimer’s disease diagnosis. EbioMedicine 3, 155–162 (2016).
- Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J. Med. Chem. 46(13), 2740–2754 (2003).
- Gibson GE, Hirsch JA, Cirio RT, Jordan BD, Fonzetti P, Elder J. Abnormal thiamine-dependent processes in Alzheimer’s Disease. Lessons from diabetes. Mol. Cell Neurosci. 55, 17–25 (2013).
- Chen Z, Zhong C. Decoding Alzheimer’s disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies. Progr. Neurobiol. 108, 21–43 (2013).
- Heroux M, Raghavendra Rao VL, Lavoie J, Richardson JS, Butterworth RF. Alterations of thiamine phosphorylation and of thiamine-dependent enzymes in Alzheimer’s disease. Metab. Brain Dis. 11(1), 81–88 (1996).
- Mastrogiacoma F, Bettendorff L, Grisar T, Kish SJ. Brain thiamine, its phosphate esters, and its metabolizing enzymes in Alzheimer’s disease. Ann. Neurol. 39(5), 585–591 (1996).
- Butterworth RF, Besnard AM. Thiamine-dependent enzyme changes in temporal cortex of patients with Alzheimer’s disease. Metab. Brain Dis. 5(4), 179–184 (1990).
- Zhao Y, Pan X, Zhao J, Wang Y, Peng Y, Zhong C. Decreased transketolase activity contributes to impaired hippocampal neurogenesis induced by thiamine deficiency. J. Neurochem. 111(2), 537–546 (2009).
- Pan X, Gong N, Zhao J et al. Powerful beneficial effects of benfotiamine on cognitive impairment and beta-amyloid deposition in amyloid precursor protein/presenilin-1 transgenic mice. Brain 133(Pt 5), 1342–1351 (2010).